Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose esketamine after cesarean delivery for prevention of postpartum depressive symptoms
ChiCTR2400080617Phase 4Not yet recruiting
- Sponsor
- Xi'an International Medical Center Hospital
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine in postpartum depression (PPD) (5 arms), sponsored by Xi'an International Medical Center Hospital. Primary endpoint: Edinburgh Postnatal Depression Scale. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on ChiCTR2400080617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080617.